UBS Group’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-29,200	Closed	-$1.42M	–	7931
2020 Q2	$1.42M	Buy	+29,200	New	+$1.4M	﹤0.01%	3200
2020 Q1	–	Sell	-47,000	Closed	-$2.01M	–	7906
2019 Q4	$2.01M	Buy	+47,000	New	+$2.04M	﹤0.01%	3541
2016 Q1	–	Sell	-2,900	Closed	-$103K	–	7574
2015 Q4	$103K	Hold	2,900	–	–	﹤0.01%	5177
2015 Q3	$96K	Sell	2,900 -400	-12%	-$16.6K	﹤0.01%	5267
2015 Q2	$138K	Sell	3,300 -30,200	-90%	-$1.17M	﹤0.01%	5163
2015 Q1	$1.09M	Sell	33,500 -40,300	-55%	-$1.39M	﹤0.01%	3491
2014 Q4	$2.34M	Buy	+73,800	New	+$2.09M	﹤0.01%	2752

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's ACAD Position: Q2 2026 in Review

UBS Group increased its Acadia Pharmaceuticals (ACAD) stake by 2.6% in Q2 2026, buying an estimated $253K and bringing the position to 460,053 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3282.

UBS Group first reported a position in ACAD in Q4 2014 and has held it in 47 quarters since. The position peaked at $22.8M in Q4 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

UBS Group held 460,053 shares of Acadia Pharmaceuticals worth $11.6M as of Q2 2026.
UBS Group bought 11,504 Acadia Pharmaceuticals shares in Q2 2026, an estimated $253K.
Acadia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3282 holding.
UBS Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
UBS Group's Acadia Pharmaceuticals position peaked at $22.8M in Q4 2024.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.